Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following Director share transactions.

The Company was notified on 12 May 2025 that on the same day, Individual Savings Accounts ("ISA's") held in the name of Susan Searle, Non-Executive Director, purchased 5,000 ordinary shares of 5p each ("Ordinary Shares") at a price of 194.83p per Ordinary Share and ISA's held by Fraser Searle, husband and a PCA of Susan Searle, purchased 5,000 Ordinary Shares at a price of 194.83p per Ordinary Share. Following these transactions, Susan Searle and persons closely associated hold 0.005% of the issued share capital.

As part of the Share Incentive Plan ("SIP") and Employee Share Purchase Plan ("ESPP), Executive Directors and employees can sacrifice part of their annual bonus and/or salary into the SIP and ESPP, which for every share purchased on behalf of the employee they receive matching shares which are deferred for a minimum of three years. Chris Meredith (CEO) and Eddie Johnson (CFO) have elected to sell certain existing shares to use the proceeds to re-invest in the SIP and ESPP.

The Company was notified on 12 May 2025 that following his decision to participate Chris Meredith, who is a Director and PDMR, executed the exercise of 64,000 nil-cost options from the existing Long Term Incentive Plan ("LTIP") and subsequently sold 64,000 Ordinary Shares of 5p each on 12 May 2025 at a share price of 194.61p per Ordinary Share. The proceeds from the sale of the shares were used to purchase shares in the SIP and ESPP, as detailed below.

The Company was further notified on 12 May 2025 that following his decision to participate Eddie Johnson, who is a Director and PDMR, executed the exercise of 28,126 nil-cost options from the existing Long Term Incentive Plan ("LTIP") and subsequently sold 28,126 Ordinary Shares of 5p each on 12 May 2025 at a share price of 196.4p per Ordinary Share. The Company was further notified on 13 May 2025 that Eddie Johnson had exercised 16,402 nil-cost Matching Shares from the ESPP and subsequently sold 16,402 Ordinary Shares of 5p each on 13 May 2025 at a share price of 194.62p per Ordinary Share. The proceeds from the sale of the shares were used to purchase shares in the SIP and ESPP, as detailed below.

The Trust which manages the SIP and ESPP on behalf of the employees of AMS has purchased Ordinary Shares of 5p each ("Ordinary Shares") on 12 May 2025, at a share price of 195.04p on behalf of Chris Meredith (923 Ordinary Shares into the SIP, 32,168 Ordinary Shares into the ESPP) and Eddie Johnson (923 Ordinary Shares into the SIP, 20,669 Ordinary Shares into the ESPP), who are both Directors/PDMRs, as part of the SIP and, under the terms of the SIP and ESPP, these shares will be held in trust on their behalf. The Company was notified of the completion of these purchases on 15 May 2025.

In addition Chris Meredith and Eddie Johnson further exercised outstanding nil-cost LTIPs and nil-cost ESPP Matching Shares in order to transfer them into their own names, selling a proportion to cover tax and National Insurance.

The Company was notified on 12 May 2025 that Chris Meredith exercised 307,210 nil-cost LTIPs and 114,518 nil-cost ESPP Matching Shares and subsequently sold 211,521 Ordinary Shares at a share price of 193.80p per Ordinary Share on 12 May 2025, retaining 210,207 Ordinary Shares in his own name.

The Company was notified on 13 May 2025 that Eddie Johnson exercised 130,776 nil-cost LTIPs, 86,184 nil-cost ESPP Matching Shares and 12,737 Deferred Bonus Shares and subsequently sold 115,206 Ordinary Shares at a share price of 194.62p per Ordinary Shares on 13 May 2025, retaining 114,491 Ordinary Shares in his own name.

The number of shares held by Chris Meredith and Eddie Johnson and their PCAs will increase their beneficial interest in the Company from the level prior to these transactions and the beneficial ownership of Chris Meredith and Eddie Johnson are as follows:

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

- Ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com.